|
The production linked incentive (PLI) schemes for bulk drugs has resulted in cumulative sales of Rs. 2,315.44 crore, reducing imports worth Rs. 1,807.32 crore till September, 2025, according to the ministry of chemicals and fertilisers.
Union minister of state in the ministry of chemicals and fertilizers, Anupriya Patel, in a written reply in Rajya Sabha, said that as of September 2025, under the PLI scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates (DIs) and active pharmaceutical ingredients (APIs), production capacities have been created for 26 KSMs/DIs/APIs, which were earlier primarily imported.
Till September 2025, investment of Rs. 4,763.34 crore has already been made in three and half years of scheme production, against an investment commitment of Rs. 4,329.95 crore over the period of six years. Further, the scheme has resulted in cumulative sales of Rs. 2,315.44 crore reported till September 2025, including exports of Rs. 508.12 crore, thereby avoiding imports worth Rs. 1,807.32 crore, said the Minister.
The scheme, which has a total budgetary outlay of Rs. 6,940 crore, aims to avoid disruption in supply of critical APIs used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source.
Commenting on the PLI scheme for Pharmaceuticals, another scheme to promote domestic manufacturing of medicines, the Minister said that as of September 2025, in three and half years of scheme operation, domestic cumulative sales of APIs and drug intermediates worth Rs. 26,123 crore have taken place, which includes sales of 191 new APIs and drug intermediates produced for the first time under the scheme.
The scheme has a total budgetary outlay of Rs. 15,000 crore, with aim to enhance India’s manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. as well as production of APIs/DIs/KSMs other than those notified under the PLI scheme for bulk drugs.
Under the Scheme for Promotion of Medical Devices Parks, having a total outlay of Rs. 300 crore, three parks have been approved and are being developed in Greater Noida (Uttar Pradesh), Ujjain (Madhya Pradesh) and Kanchipuram (Tamil Nadu).
The Minister said that Rs. 180 crore have been released in two instalments for development of common infrastructure facilities at these three parks. The civil work for common facilities in all three medical device parks is at the final stage of construction.
As of September 2025, 194 medical devices manufacturers have been allotted land in the approved Medical Devices Parks in a 298.58-acre area and construction has commenced for 34 units, added the Minister.
|